30 closest matches · ranked by relevance
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Ovarian Cancer
Primary: PFS — 29.8 Months
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
High-grade Serous Ovarian Carcinoma · Ovarian Carcinoma
Primary: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) — 0.08; 0.04 Fold change
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Carcinoma
Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed…
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Neoplasms, Ovarian
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 20.0; 13.9 Percent of participants